Back

Real world experience from 1000 patients. Preprocedural DOAC interruption impacts detectable DOAC serum levels but not adverse events after catheter ablation of atrial fibrillation.

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Atrial Fibrillation ePosters Rhythm Control, Catheter Ablation ESC Premium Access ESC Congress 2020

About the speaker

Photo
Mr Athanasios Konstantinou

CardioVascular Center Bethanien (CCB), Frankfurt (Germany)

172 More presentations in this session

Presentation thumbnail
Atrial fibrillation with or without structural abnormalities. Analysis from a nationwide database.
Doctor V. Mertz (FR)
Abstract Slides
Presentation thumbnail
Epicardial adipose tissue and atrial fibrillation: guilty as charged or guilty by association?
Doctor J. Sousa (Funchal, PT)
Abstract Slides
Presentation thumbnail
Timing and degree of left atrial stunning and reverse functional remodeling following electrical cardioversion in patients with recent onset atrial fibrillation
Doctor P. Arvanitis (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Irregular beat-to-beat hemodynamic properties determine left ventricular function during atrial fibrillation
Doctor A. Lyon (Maastricht, NL)
Abstract Slides
Presentation thumbnail
Genetic susceptibility, elevated blood pressure and risk of atrial fibrillation
Mr M. Nazarzadeh (Oxford, GB)
Abstract Slides

Access the full session

Session thumbnail
Atrial Fibrillation ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Safety and efficacy of anticoagulation therapy post atrial fibrillation ablation
9 March 2024
thumbnail
Congress Presentation
Clinical outcomes after reversal of dabigatran in daily practice: real-world use of idarucizumab 2015-2019
28 August 2020
thumbnail
Congress Presentation
Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF Registry sub-cohort analysis
31 August 2020
thumbnail
Congress Presentation
Interrupted vs uninterrupted direct oral anticoagulants compared with uninterrupted vitamin K antagonists for atrial fibrillation ablation - A meta-analysis of safety
31 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources